Literature DB >> 26835391

Liver tumors in children with metabolic disorders.

Deborah A Schady1, Angshumoy Roy1, Milton J Finegold1.   

Abstract

Hepatic neoplasia is a rare but serious complication of metabolic diseases in children. The risk of developing neoplasia, the age at onset, and the measures to prevent it differ in the various diseases. We review the most common metabolic disorders that are associated with a heightened risk of developing hepatocellular neoplasms, with a special emphasis on reviewing recent advances in the molecular pathogenesis of the disorders and pre-clinical therapeutic options. The cellular and genetic pathways driving carcinogenesis are poorly understood, but best understood in tyrosinemia.

Entities:  

Keywords:  Cirrhosis; hemochromatosis; tyrosinemia; α-1 antitrypsin (AAT)

Year:  2015        PMID： 26835391      PMCID： PMC4728996          DOI： 10.3978/j.issn.2224-4336.2015.10.08

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN： 2224-4336


  89 in total

1.  Hepatocellular carcinoma in an adult patient with type IV glycogen storage disease.

Authors:  Ibrahim Koral Onal; Nesrin Turhan; Erkin Oztas; Mehmet Arhan; Zuhal Akcoren; Perihan Oguz; Meral Akdogan; Eda Demir Onal; Sabite Kacar; Mevlut Kurt; Nurgul Sasmaz
Journal:  Acta Gastroenterol Belg       Date:  2009 Jul-Sep       Impact factor: 1.316

Review 2.  Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency.

Authors:  David R Nelson; Jeffrey Teckman; Adrian M Di Bisceglie; David A Brenner
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-23       Impact factor: 11.382

3.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

4.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

5.  Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?

Authors:  C J L Koelink; P van Hasselt; A van der Ploeg; M M van den Heuvel-Eibrink; F A Wijburg; C M A Bijleveld; F J van Spronsen
Journal:  Mol Genet Metab       Date:  2006-09-27       Impact factor: 4.797

6.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson; J Carlson; R Velez
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

Review 7.  Alpha-1-antitrypsin deficiency.

Authors:  D H Perlmutter
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

8.  The liver in adolescents with alpha 1-antitrypsin deficiency.

Authors:  T Sveger; S Eriksson
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

9.  Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z.

Authors:  Sager J Gosai; Joon Hyeok Kwak; Cliff J Luke; Olivia S Long; Dale E King; Kevin J Kovatch; Paul A Johnston; Tong Ying Shun; John S Lazo; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

10.  Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency.

Authors:  Shujuan Pan; Lu Huang; John McPherson; Donna Muzny; Farshid Rouhani; Mark Brantly; Richard Gibbs; Richard N Sifers
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425
View more
  7 in total

Review 1.  Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Authors:  Teodoro Jerves; Nenad Blau; Carlos R Ferreira
Journal:  Mol Genet Metab       Date:  2022-03-28       Impact factor: 4.204

2.  Clinical experience with hepatorenal tyrosinemia from a single Egyptian center.

Authors:  Hanaa El-Karaksy; Hala Mohsen Abdullatif; Carolyne Morcos Ghobrial; Engy Adel Mogahed; Noha Adel Yasin; Noha Talal; Mohamed Rashed
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.752

Review 3.  Hepatocellular adenoma in the paediatric population: Molecular classification and clinical associations.

Authors:  Elan Hahn; Juan Putra
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

4.  mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model.

Authors:  Maximiliano L Cacicedo; Christine Weinl-Tenbruck; Daniel Frank; Sebastian Wirsching; Beate K Straub; Jana Hauke; Jürgen G Okun; Nigel Horscroft; Julia B Hennermann; Fred Zepp; Frédéric Chevessier-Tünnesen; Stephan Gehring
Journal:  Mol Ther Methods Clin Dev       Date:  2022-07-15       Impact factor: 5.849

Review 5.  Rare Inherited Cholestatic Disorders and Molecular Links to Hepatocarcinogenesis.

Authors:  Rebecca Jeyaraj; Deirdre Kelly
Journal:  Cells       Date:  2022-08-18       Impact factor: 7.666

6.  In vivo quantitative photoacoustic evaluation of the liver and kidney pathology in tyrosinemia.

Authors:  Guojia Huang; Jing Lv; Yong He; Jian Yang; Lvming Zeng; Liming Nie
Journal:  Photoacoustics       Date:  2022-09-28

Review 7.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.